New depression drug shows early promise in mood and alertness

NCT ID NCT06391593

Completed Disease control Sponsor: Alto Neuroscience Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental drug called ALTO-203 in people with moderate depression and loss of pleasure (anhedonia). Researchers gave 69 participants either the drug or a placebo to see how it affected their mood and alertness, and to check if it was safe. The goal was to gather information to see if the drug could help control depression symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site 4005

Orlando, Florida, 32801, United States
Site 4007

Clinton, Utah, 84015, United States
Site 4022

Marlton, New Jersey, 08053, United States
Site 4023

Torrance, California, 90504, United States
Site 4031

Atlanta, Georgia, 30030, United States
Site 4033

Bellevue, Washington, 98007, United States
Site 4036

Las Vegas, Nevada, 89121, United States
Site 4040

Austin, Texas, 78737, United States
Site 4054

Pikesville, Maryland, 21208, United States
Site 4058

Tucson, Arizona, 85704, United States
Site 4059

Clermont, Florida, 34711, United States
Site 4072

Houston, Texas, 77081, United States
Site 4075

Westlake, Ohio, 44145, United States
Site 4082

Oceanside, California, 92056, United States
Site 4134

Princeton, New Jersey, 08540, United States

Conditions

Explore the condition pages connected to this study.

ANHEDONIA MAJOR DEPRESSIVE DISORDER